The aims of the current review were to compare the efficacy of monotherapy with bendroflumethiazide vs. indapamide on mortality, cardiovascular outcomes, blood pressure, need for intensification of treatment and treatment withdrawal. Two authors independently screened the results of a literature search, assessed the risk of bias and extracted relevant data. Randomized clinical trials of hypertensive patients of at least a 1-year duration were included. When there was disagreement, a third reviewer was consulted. Risk ratio (RR) and mean differences were used as measures of effect. Two trials comparing bendroflumethiazide against placebo, one comparing indapamide with placebo and three of short duration directly comparing indapamide and Bendroflumethiazide, were included. No statistically significant difference was found between indapamide and bendroflumethiazide for all deaths [RR 0.82 (RR 0.89; 95% CI 0.67, 1.18). Indapamide performed worse for stroke (RR 2.21; 95% CI 1.19, 4.11), even though a reduction in RR compared with placebo was observed in both groups. There was no statistically or clinically significant difference between indapamide and bendroflumethiazide in blood pressure reduction (mean absolute difference <1 mmHg). The present review highlights a lack of studies to answer the review question but also a lack of evidence of superiority of one drug over the other. Therefore, there is a clear need for new studies directly comparing the effect of these drugs on the outcomes of interest.
Introduction
High blood pressure (BP) is one of the most important preventable causes of premature cardiovascular morbidity and mortality worldwide. The World Health Organization (WHO) estimates that the global prevalence in adults aged 25 years and over is around 40%. Raised BP is estimated to cause 7.5 million deaths annually, about 12.8% of the total of all deaths. Moreover, hypertension increases the risk of developing coronary artery disease, stroke, heart failure, peripheral vascular disease, vision loss, chronic kidney disease, cognitive decline and early death [1] . Treating hypertension reduces cardiovascular disease risk and the risk of death from cardiovascular causes [2] . Thiazide diuretics are a class of antihypertensive medications launched in the 1950s and have long demonstrated effectiveness in reducing BP and the risk of cardiovascular events [3] . A recent Cochrane systematic review of first-line drugs for hypertension concluded that ʻlow-dose thiazides should be the first-choice drug in most patients with elevated blood pressureʼ due to the evidence of reduced mortality and morbidity such as stroke, heart attack and heart failure [4] . Usually prescribed as first-or second-line drugs, alone or combined with drugs from other classes [5, 6] , diuretics are classified into thiazides and thiazide-like diuretics [7] . The most recent National Institute for Health and Clinical Excellence (NICE) guidelines for the management of hypertension published in 2011 [8] and evidence updated in 2013 [9] specified that if ʻ … a diuretic is requiredʼ, ʻ… a thiazide-like diuretic, such as chlorthalidone (12.5-25 mg once daily) or indapamide (2.5 mg once daily)ʼ should be
Inclusion and exclusion criteria
Randomized controlled trials of adults with primary hypertension with at least one year of follow-up were included. Studies reporting monotherapy with bendroflumethiazide or indapamide were included when the comparator group was either a placebo or another drug. Studies including supplemental medication with other drug classes as stepped-care therapy could also be included. It was assumed that these supplemental drugs did not systematically interact to affect the occurrence of the outcomes studied.
Data extraction
Two reviewers independently screened the title and the abstract of each study meeting the inclusion criteria. If disagreements occurred between the two reviewers, a third reviewer was consulted. For eligible studies, data extraction was performed by two reviewers independently, using a specially designed data collection form. Disagreements were resolved after discussion with two other reviewers. The values of mean change from baseline in BP at the 1-year follow-up and the standard deviation were obtained from Wright and Musini (2009) [4] . Authors of studies were contacted, when the required information was clearly available but not reported in the manuscript.
Outcomes
The primary outcomes considered were total mortality and cardiovascular outcomes such as stroke, myocardial infarction, congestive heart failure and cardiovascular death. The secondary outcomes were adverse events, need for intensification of treatment, withdrawals and BP lowering. Only published information was used.
Risk of bias in the included studies
The Cochrane Collaboration's tool for assessing risk of bias [20] was used to assess quality in the included studies. The items of methodological quality assessed were: method used to randomize participants; whether randomization was completed in an appropriate and blinded manner; whether participants, providers, outcome assessors or a combination of these were blinded to the assigned therapy; whether the control group received a placebo or no treatment; the percentage of participants who did not complete follow-up (drop-outs); the percentage of participants not on assigned active or placebo therapy at study completion; and the selective reporting of outcomes. Two reviewers conducted the assessment independently. If disagreement occurred, a third reviewer was consulted. The results were compared with those reported by Musini et al. [14, 21] .
Data analysis
Network meta-analysis was conducted using STATA 15 for Windows (2017). All analyses were by intent-to-treat. Indirect comparisons were made using the indirect STATA command [22] . Graphical tools [23] were used as appropriate. Evidence was graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) [24] Working Group, using GRADEpro [25] .
Results

Search results
The search resulted in 1878 publications (Figure 1 ). After the removal of duplicates and 1418 irrelevant papers, and having found an additional 26 papers by hand searching the references of published papers, 128 full-text papers were considered further. The reasons for exclusion of 112 articles are shown in Figure 1 . A total of 52 reviews, meta-analyses, commentaries, editorial and protocols were found, and a further 60 articles contained information from 53 individual studies. The most common reason for study exclusion was duration of treatment (<1 year) (n = 22) followed by the use of combination therapy (n = 13) and studies not being trials of hypertension (n = 12). Other excluded studies were observational studies (n = 3), single-arm trials (n = 3), studies that did not include bendroflumethiazide or indapamide (n = 5) and studies using any thiazide diuretic rather than specifically bendroflumethiazide (n = 4).
Three further studies [the Hypertension in the Very Elderly Trial (HYVET) pilot [26] ; Diuretics in the Management of Essential Hypertension (DIME) study [27] and Heart Attack Primary Prevention in Hypertension (HAPPHY) trial [28] were excluded because the participating centres within each study were given the choice of type of thiazide diuretics depending on drug availability, but the published manuscripts did not report the results by type of drug. When contacted, the authors or funders either did not reply, could not provide the information required or could not make the original datasets available for data analysis. Therefore, three studies reported in 17 papers were included in the present review [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
As no studies of a direct comparison between indapamide and bendroflumethiazide for long-term outcome were found, we included three studies of short-term follow-up with BP as an outcome [45] [46] [47] .
Description of the included studies and study participants
Two studies were conducted in the UK [29, 31] and one study was a multicentre clinical trial [39] (Table 1) . They were published between 1973 and 2008. Study size ranged from 116 to 17 354 participants, and females comprised between 48% and 60%. Two studies included participants of mean age around 50-55 years, while in one study [39] the mean age of participants was 84 years. In two studies, participants were followed up annually for 5 years [31, 39] and one study followed the participants up to 18 months [27] .
All studies had pharmaceutical industry sponsorship. Participants were recruited from a variety of sources, such as hospitals, primary care and surveys of random samples of the general population (Table 2) . Mild, moderate and persistent hypertension were used as inclusion criteria, and there was variation in the method of BP measurement ( Table 2) . Two studies investigated bendroflumethiazide [29, 31] and one study investigated indapamide [37] (Table 3 ). All three trials used placebo as a comparison and one study also used propranolol [31] . Doses of all medications varied, and one study [29] did not specify the dose. All studies permitted additional medication at the discretion of the physician or trial investigators (Table 3) . Three short-term outcome studies directly comparing indapamide and bendroflumethiazide are described in Appendix 4. They were conducted in 1981 [45, 46] and 2006 [47] , each included fewer than 30 participants and the follow-up was between 4 weeks and 16 weeks. Table 4 shows the availability of data on primary and secondary outcomes. Two trials [31, 39] had all primary outcomes data available, but the cause of death was missing for two 
Definition of outcome
Figure 1
Flow diagram participants in the placebo group in Barraclough et al. [29] All studies reported withdrawals for medical reasons; however, the reported reasons differed between studies. For example, in the study by Barraclough et al. [29] , participants in the placebo group with a diastolic BP >130 mmHg were withdrawn by design. There were insufficient data for other secondary outcomes, such as additional medication, but data on diastolic BP were reported in all studies and information on systolic BP was available in two studies [31, 39] .
Risk of bias in the included studies Table 5 shows the results of the assessment of risk of bias in each of the included studies. Two studies [29, 31] did not satisfy the criteria for blinding and data completeness, two studies [29, 39] were not free of selective reporting, one trial [29] had inadequate allocation concealment and in one study [39] random sequence generation was unclear. Appendix 5 shows results of the assessment of risk of bias in each of the three short-term outcome studies directly comparing indapamide and bendroflumethiazide. All three studies had a high risk of bias.
Effects of interventions
Appendix 1 shows the data extracted for each outcome and effect of intervention for each study compared with placebo, and Appendix 2 shows a forest plot by outcome for each study. Significant long-term reductions in BP from baseline, in comparison with placebo, were reported in all studies. There were no statistically or clinically significant differences between indapamide and bendroflumethiazide in systolic and diastolic BP (mean difference in reduction from baseline 0.94 mmHg; 95% CI -1.45, 2.25, and 0.88 mmHg; 95% CI -0.19, 1.95, respectively) (Appendices 1 and 2). Appendix 6 shows data extracted for systolic and diastolic BP for each study of the direct comparison between indapamide and bendroflumethiazide, and Appendix 7 shows a forest plot and summary effects. There was no statistically or clinically significant difference between indapamide and bendroflumethiazide in systolic and diastolic BP (mean difference -0.26 mmHg; 95% CI -0.79, 0.27, and -0.40 mmHg; 95% CI -0.93, 0.14, respectively) (Appendix 7). There were only three studies included in the meta-analysis of long-term outcomes, and three studies of short-term BP reduction. Appendix 8 shows funnel plots for these studies. There did not appear to be any evidence of publication bias for short-term outcomes as the figures for both types of BP were symmetrical. However, this was less clear in the case of indirect comparisons.
Overall evidence
Evidence was graded either as moderate or low (Tables 6  and 7) .
Discussion
Bendroflumethiazide and indapamide are the most frequently prescribed diuretics for hypertension treatment in the UK [48] . This is the first systematic review directly to compare these agents. It demonstrates the lack of evidence on the comparative effectiveness of these drugs on mortality and cardiovascular outcomes such as stroke and myocardial [49] .
A network meta-analyses that aimed to summarize the evidence on the efficacy of antihypertensive therapies [16] included 42 clinical trials randomized to seven types of treatment. Treatments considered were placebo, untreated or usual care: low-dose diuretics, β-blockers, angiotensinconverting enzyme inhibitors; angiotensin II receptor blockers, calcium channel blockers and α-blockers. The latter meta-analysis showed that low-dose diuretics were the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality compared with other treatments. However, the low-dose diuretic therapies were usually the equivalent of 12.5-25 mg per day of chlorthalidone or hydrochlorothiazide.
Although the present review included only a limited number of studies, its strengths included having a predefined protocol and the fact that it followed current guidelines and statistical techniques. Every effort was made to find relevant studies, and multiple sources were searched. The search strategy was similar to those strategies used in a previous systematic review [4] and clinical guidelines update [9] . To minimize potential errors, the selection of studies and data extraction were performed independently by two reviewers, and the data were also compared with those extracted in other systematic reviews [14, 21] .
Nevertheless, there were several methodological limitations. We restricted our search to publications in the English language, which could potentially have influenced the results. However, in other countries, other types of thiazide, such as chlorthalidone, metolazone or hydrochlorothiazide, are mostly used [50] [51] [52] [53] . Although one study [39] included in the present review was international, all of the other studies were conducted only in the UK [29, 31] .
We formally evaluated publication bias, but the number of studies included in the present review was small. It is possible that some studies, especially earlier studies, were never published. We searched clinical trials registers, as well as databases of published literature, but were unable to find any further studies. Although three studies eligible for inclusion had the required data available, we could not get access to the original data and therefore could not include them in the present review.
There was substantial heterogeneity between the included studies. Firstly, hypertension was defined differently between the studies. For example, the HYVET study [39] considered systolic BP, whereas the others [29, 31] considered diastolic BP.
Studies also measured BP differently -that is, supine, sitting or standing, and clinic or monitoring at home; or as a one-off measurement or average of measurements from several occasions. Inclusion criteria were different between the studies. In the HYVET study [39] , patients had been previously treated for hypertension but had suspended their treatment for at least 2 months prior to entry to the study, whereas in the other two trials [29, 31] the enrolled participants had not taken any medication for hypertension prior to enrolment.
Participants were recruited from various sources, such as the general population, medical practices and hospitals; therefore, it was difficult to judge the overall generalizability of the findings.
One study [29] had a follow-up of 18 months, whereas two other studies had a long-term follow-up (over 5 years).
However, the results of a 2-year follow-up were also available for the HYVET study [37] , and of a 5.5-year follow for the Medical Research Council Therapy for Mild Hypertension (MRC-TMH) study [31] . In addition, it was possible to estimate the BP results for a 1-year follow up from the graphs published in all three papers. Dose information was not available in one study [29] .
Another potential limitation was the fact that some of the trials included a thiazide combined with another drug. For example, in the HYVET study [39] , at the 2-year follow-up, 73.4% of the active group received both indapamide and perindopril. Outcome data were not always complete or were heterogeneous. For example, cause of death was missing for some participants in the study by Barraclough et al. [29] . The latter study also withdrew controls with a diastolic BP >130 mmHg but not patients in the active group. There were different reasons for medical withdrawals, as well as inconsistent reports of nonmedical withdrawals, between studies. Additional medication was insufficiently reported to allow meaningful data analysis. One study [29] did not report data on systolic BP. Data for some parameters, such as standard deviation, were not always available, especially in the earlier studies, and therefore assumptions were made using baseline estimates or estimates from other studies. This could potentially have introduced bias to the overall estimates.
The quality of the included studies varied -for example, two trials (one long-term [39] and one short-term [47] ) were double blind. Two studies were large [31, 39] , whereas the study by Barraclough et al. [29] and three studies of direct comparison were relatively small (fewer than 30 participants).
All long-term studies and one short-term study reported some form of pharmaceutical industry support. However, although it is widely agreed that it is important to know the provenance of funding for a study, it has been argued that the Cochrane risk of bias tool should not include funding source as a standard item [54] . Conflicts of interest in industry-funded trials are likely to manifest in selective reporting or a problematic choice of comparator. To counteract the former, we searched trial registers and, where possible, accessed study protocols. To counteract the latter, it has been suggested that network meta-analysis can be used for head-to-head drug comparisons when placebo comparators have been used [54] , and this was used in the present review.
There were several potential methodological problems associated with indirect comparisons [55] . Although the combined sample size of the included studies was large, the number of studies available for the present review was small. Methods for estimating the effective number of trials and effective sample size have been proposed which take into account the trial count ratio [55] . For a trial count ratio of 1:2 (e.g. in the present review, there were two studies of bendroflumethiazide and one study of indapamide), the indirect comparison would require six trials (ratio 2:4) to produce a precision equivalent to one head-to-head trial [56] .
We did not combine indirect and direct evidence, as the direct evidence came from small short-term trials reporting BP only, whereas the primary aim of the study was to compare long-term cardiovascular outcomes. However, it was reassuring that both direct and indirect estimates of the drug effects on BP were similar. In addition, reduced BP seemed to stabilize after 1 year of follow-up [31, 39] .
We compared bendroflumethiazide and indapamide indirectly via placebo. The composition of the placebo was included in only one trial [29] , whereas the other studies stated that placebo was essentially a ʻlook-alikeʼ version of the active treatment. Although there were studies of direct comparisons of hydrochlorothiazide vs. indapamide and hydrochlorothiazide vs. placebo [4, 49] , they were not included because these drugs are rarely used in the UK [48] .
One of the requirements of an indirect meta-analysis is that the population groups are comparable. Two studies in the present review involved participants below the age of 80 years [29, 31] , and one study [39] was conducted in patients aged over 80 years. One might argue that these groups are not comparable. Is there any evidence of a differential action of these drugs in different age groups? A systematic review of pharmacotherapy for hypertension in adults aged 18-59 years [14] included seven studies and 17 327 participants, but the MRC-TMH trial [31] , which was also included in the current review, contributed 84% of the population considered. The review [14] demonstrated a small absolute effect in reducing cardiovascular mortality and morbidity, no reduction in all-cause mortality or coronary events, and a lack of good evidence on withdrawal due to adverse events.
However, a systematic review of pharmacotherapy for hypertension in the elderly [21] included 15 trials and 24 055 participants aged ≥60 years with moderate to severe hypertension. It showed a reduction in all-cause mortality and cardiovascular morbidity and mortality, but the decrease in all-cause mortality was limited to persons aged 60-80 years. Indapamide vs. bendroflumethiazide
The process of grading the evidence is subjective, and the issue of grade inflation has been highlighted previously [57] . In the present review, evidence was graded either as low or moderate, and grading was done by author consensus, to minimize potential overestimation. Guidance for policy makers in interpreting indirect treatment comparisons and network meta-analysis is available [58, 59] ; however, our results are unlikely to be used for clinical decision-making owing to a deficiency of evidence.
In the present systematic review, we determined, from a small number of studies, that there is limited information on direct comparisons between indapamide and Bendroflumethiazide, and that the evidence of superiority of indapamide over bendroflumethiazide in long-term outcomes is inconclusive. Therefore, there is a clear need for large clinical trials directly comparing these two drugs. In fact, there are two ongoing studies. The Bendroflumethiazide versus Indapamide for Primary Hypertension: Observational (BISON) [60] study within the Clinical Practice Research Datalink [61] is designed to compare the effect of bendroflumethiazide vs. indapamide on the risk of cardiovascular outcomes using real-world data. The Evaluating Diuretics in Normal Care (EVIDENCE) study is a clusterrandomized evaluation of hypertension prescribing policy in which primary care surgeries have their practice drug formularies randomized to either indapamide or bendroflumethiazide [62] .
In summary, we found no good comparative effectiveness data on the two most commonly prescribed diuretics for hypertension in the UK.
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [63] . 
